Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276423 | 0.88 | AKR1C3 (0.46) | AKR1C3LMNAFAAHMEN1KMT2A | |
| SCHEMBL17276715 | 0.87 | AKR1C3 (0.52) | AKR1C3LMNAGAAMAPTHTT | |
| SCHEMBL17276384 | 0.85 | AKR1C3 (0.56) | AKR1C3LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL19078781 | 0.85 | AKR1C3 (0.58) | AKR1C3FAAHMGLLTSHRAVPR1A | |
| SCHEMBL17276598 | 0.85 | AKR1C3 (0.58) | AKR1C3LMNAGAAMAPTFAAH | |
| SCHEMBL17281610 | 0.83 | AKR1C3 (0.42) | AKR1C3LMNAGAAMAPTXBP1 | |
| SCHEMBL17276600 | 0.83 | FAAH (0.56) | AKR1C3LMNAGAAMAPTHTT | |
| SCHEMBL17276684 | 0.81 | NCF1 (0.61) | LMNAMAPTHTTSMN1; SMN2TSHR | |
| SCHEMBL17276443 | 0.81 | AKR1C3 (0.52) | AKR1C3LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL17276570 | 0.81 | ALDH1A1 (0.55) | GAAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | AKR1C3 1992/4885LMNA 4598/4885GAA 2974/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | AKR1C3 1992/4885LMNA 4598/4885GAA 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.